A class action claims Florida-based BPI Sports' bodybuilding and dietary supplements "contain a dangerous amphetamine-like ingredient that poses a serious health risk and has potentially life-threatening side effects."
BPI's best selling products include '1.M.R' powder and tablets, 'RoxyLean ECA' and 'Rx6' (collectively, the 'products.') These products are purported dietary supplements which are marketed for use as bodybuilding and weight loss supplements. 1.M.R is marketed as a pre-workout bodybuilding supplement. RoxyLean and Rx6 are marketed as 'fat burning' weight loss supplements.
"DMAA was patented by Eli Lilly & Company in 1944 and later marketed, beginning in 1971, under the trademark 'Forthane' for use as a nasal decongestant and as a treatment for hypertrophied or hyperplasic oral tissues. DMAA is a vasoconstrictor and central nervous system stimulant which is on the World Anti-Doping Agency ('WADA') and Major League Baseball ('MLB') lists of banned substances. The sale of DMAA is totally prohibited in Canada and New Zealand. Recently, DMAA has gained popularity with young people as a designer drug used in 'party pills.'
"BPI failed to inform consumers that DMAA is a dangerous central nervous system stimulant which is banned by WADA, MLB, Canada and New Zealand, and that using the products can cause consumers to test positive for an illegal substance and/or amphetamine use., says the lawsuit.
Here are the defendants: BPI Sports LLC, BPI Sports Holdings Inc., Brian Pharma II LLC, and BPI principals Derek Ettinger and James Grage.
